Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucagon-like peptide 2.

D J Drucker1

  • 1Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada M5G 2C4. d.drucker@utoronto.ca

The Journal of Clinical Endocrinology and Metabolism
|April 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis.

Molecular metabolism·2024
Same author

Glucagon-like peptide 1 (GLP-1).

Molecular metabolism·2019
Same author

Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor.

The Journal of physiology·2012
Same author

Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.

Diabetologia·2011
Same author

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Diabetologia·2010
Same author

Smoking habits in hospital.

Canadian Medical Association journal·2010
Same journal

Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Continuous glucose monitoring-derived time in range is associated with changes in arterial stiffness in type 2 diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

From Premature Adrenarche to Adult Metabolic Risk and Hyperandrogenism: A Systematic Review and Meta-Analysis.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Correction to: "CAHQL: A Patient-Reported Outcome Instrument to Assess Health-Related Quality of Life in Congenital Adrenal Hyperplasia".

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Glucagon-like peptide 2 (GLP-2) enhances gut healing and nutrient absorption. This peptide shows potential for treating intestinal mucosal injury and dysfunction.

Area of Science:

  • Gastroenterology
  • Endocrinology
  • Molecular Biology

Background:

  • Glucagon-like peptide 2 (GLP-2) is a peptide hormone involved in nutrient absorption.
  • GLP-2 is secreted from gut endocrine cells and regulates various gastrointestinal functions.

Purpose of the Study:

  • To investigate the therapeutic potential of GLP-2 for intestinal disorders.
  • To elucidate the mechanisms by which GLP-2 exerts its effects on the gut epithelium.

Main Methods:

  • Review of existing literature on GLP-2's physiological roles and effects in preclinical models.
  • Analysis of GLP-2's impact on intestinal mucosal surface area, cell proliferation, and apoptosis.

Main Results:

  • GLP-2 enhances intestinal mucosal surface area by stimulating crypt cell proliferation and inhibiting apoptosis.

Related Experiment Videos

  • GLP-2 demonstrates cytoprotective and reparative effects in models of intestinal injury, reducing inflammation and bacterial translocation.
  • GLP-2 improves nutrient absorption and gut adaptation in conditions like short bowel syndrome.

    • Conclusions:

    • GLP-2 possesses significant cytoprotective, reparative, and energy-retentive properties.
    • GLP-2's actions are mediated through the GLP-2 receptor, a G protein-coupled receptor in the gut.
    • GLP-2 holds promise for treating human disorders involving intestinal mucosal injury or dysfunction.